Compare Amylx Pharmaceuticals Inc (AMLX) vs iShares MBS ETF (MBB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs iShares MBS ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while iShares MBS ETF trades at $92.85. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, iShares MBS ETF nearer its low. Which is the better fit depends on your goals.
| AMLX | MBB | |
|---|---|---|
Market Cap | $2.53B | — |
Sector | Health | — |
52-Week High | $24.19 | $96.91 |
52-Week Low | $7.82 | $92.72 |
Enterprise Value | $2.28B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.
Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.
MBB stock trades at $93.27, up 0.28% on the day, with technical indicators showing a bearish trend from moving averages and neutral oscillators. Recent corporate actions include dividend declarations for 2026, with payments of $0.33 and $0.34 per share. The stock lacks key valuation ratios in the provided data, suggesting limited fundamental visibility for analysis.
The outlook for MBB is cautious due to bearish technical signals and incomplete financial data. Risks include market volatility and reliance on future dividend payments for investor returns. Investment opportunity hinges on improved fundamental disclosures and positive earnings momentum, which are currently unverified.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →
